Form 144 Apellis Pharmaceuticals, Filed by: Townsend Adam J.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St futures muted as bond yields resume climb; Walmart drops after results
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Crypto stocks surge as Bitcoin short squeeze hits record $2.7B
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Citi Comments on Apellis Pharmaceuticals (APLS), Moves PT to $106
May 5, 2023 11:15 AM EDTCiti analyst Yigal Nochomovitz raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $106.00 (from $88.00) while maintaining a Buy rating.
The analyst comments "The first quarter of any drug launch is frequently a wildcard. Syfovre embodied this uncertainty given 1) mid-1Q23 approval, 2) temporary J-code,... More
